Sabai Global, a Chesterfield, MO-based provider custom solutions for biosafety and human research protections, received a growth investment from Thompson Street Capital Partners.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its business reach.
Led by CEO Chris Jenkins, Sabai Global is a provider of regulatory review and biosafety consulting services to pharmaceutical sponsors, CROs, academic health systems, and clinical research site networks. The company specializes in custom solutions for biosafety and human research protections through three subsidiaries, Clinical Biosafety Solutions (“CBS”), Castle IRB (“Castle”), and Shield Consulting (“Shield”). CBS provides Institutional Biosafety Committee services supporting the safe handling and storage of cell and gene therapy treatments during clinical research. Castle provides Institutional Review Board services supporting the ethical treatment of patients during clinical trials. Shield provides a suite of biosafety consulting services that complement CBS’s Institutional Biosafety Committee and Castle IRB’s offerings.
FinSMEs
06/02/2023